Dr. Snell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1513 S Grand Ave
Ste 360
Los Angeles, CA 90015Phone+1 562-735-3226
Education & Training
- Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
- Case Western Reserve University School of MedicineClass of 2002
Certifications & Licensure
- HI State Medical License 2022 - 2026
- OH State Medical License 2001 - 2026
- CA State Medical License 2018 - 2024
- IN State Medical License 2017 - 2019
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 20 citationsRandomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung CancerBalazs Halmos, Nathan A. Pennell, Pingfu Fu, Shumaila Saad, Shirish M. Gadgeel
The Oncologist. 2015-11-01 - 14 citationsTargeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia.A. D. Bulgar, Michael Snell, Jon R. Donze, E. B. Kirkland, L. Li
Leukemia. 2010-09-02 - 18 citationsPhase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.Paul M. Barr, Pingfu Fu, Hillard M. Lazarus, Nancy Horvath, Stanton L. Gerson
British Journal of Haematology. 2009-10-01
Press Mentions
- Michael Snell M.D., Joins the Oncology Institute of Hope and InnovationJune 26th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: